Format

Send to

Choose Destination
Shock. 2014 May;41 Suppl 1:62-9. doi: 10.1097/SHK.0000000000000134.

Whole blood: the future of traumatic hemorrhagic shock resuscitation.

Author information

1
*Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; †Air Force Medical Operations Agency, Lackland AFB, Texas; ‡Department of Transfusion Medicine, Orebro University Hospital, Orebro, Sweden; §Department of Immunology and Transfusion Medicine, Haukeland University Hospital; ∥Institute of Clinical Science, University of Bergen; and ¶Norwegian Navy Special Command Forces, Haakonsvern, Bergen, Norway.

Abstract

Toward the end of World War I and during World War II, whole-blood transfusions were the primary agent in the treatment of military traumatic hemorrhage. However, after World War II, the fractionation of whole blood into its components became widely accepted and replaced whole-blood transfusion to better accommodate specific blood deficiencies, logistics, and financial reasons. This transition occurred with very few clinical trials to determine which patient populations or scenarios would or would not benefit from the change. A smaller population of patients with trauma hemorrhage will require massive transfusion (>10 U packed red blood cells in 24 h) occurring in 3% to 5% of civilian and 10% of military traumas. Advocates for hemostatic resuscitation have turned toward a ratio-balanced component therapy using packed red blood cells-fresh frozen plasma-platelet concentration in a 1:1:1 ratio due to whole-blood limited availability. However, this "reconstituted" whole blood is associated with a significantly anemic, thrombocytopenic, and coagulopathic product compared with whole blood. In addition, several recent military studies suggest a survival advantage of early use of whole blood, but the safety concerns have limited is widespread civilian use. Based on extensive military experience as well as recent published literature, low-titer leukocyte reduced cold-store type O whole blood carries low adverse risks and maintains its hemostatic properties for up to 21 days. A prospective randomized trial comparing whole blood versus ratio balanced component therapy is proposed with rationale provided.

PMID:
24662782
DOI:
10.1097/SHK.0000000000000134
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center